aa aa

Emerging evidence identifies HMGB1 as a critical regulator of chemoresistance in small cell lung cancer (SCLC).

A study reveals that highly metastatic cancer cells possessing a functional Trx/TrxR axis respond robustly to the CXCL12/HMGB1 heterocomplex, exhibiting enhanced directional migration and invasiveness through CXCR4 activation.

In the acute ischemic phase, HMGB1 protein contributes to thromboinflammation, blood–brain barrier disruption, and immune cell activation, amplifying tissue injury.

Recent findings provide mechanistic clarity, positioning Selenoprotein O (SelO) as a negative regulator of HMGB1-driven inflammation and ROS-dependent neutrophil extracellular trap (NET) formation.

We are glad to announce an interesting paper from Prof Claudia Biguetti, about a study in which has been used 3S-HMGB1, LPS-Free (HM-130) produced by HMGBiotech.

HMGB1 is a key architectural chromatin protein whose biological effects are highly context dependent. Recent findings reveal a distinct and cancer-specific role of the HMGB1 BoxA domain in regulating DNA integrity in lung cancer cells.

High Mobility Group Box 1 (HMGB1) has emerged as a critical endogenous danger signal (DAMP), increasingly recognized for its role in orchestrating the inflammatory microenvironment in chronic respiratory diseases.

Aging continues to be a central theme in biomedical research, and HMGB1 has emerged as a critical player in the chronic, low-grade inflammation that underpins many age-related conditions.

Recent findings highlight the multifaceted involvement of HMGB1 (High Mobility Group Box 1) in both tumor-promoting mechanisms and immune modulation, making it a critical molecular node in pancreatic cancer biology.